Business Description
Akeso Inc
ISIN : KYG0146B1032
Share Class Description:
FRA:4RY: Ordinary SharesTotal Employee Number:
3,761Compare
Compare
Traded in other countries / regions
09926.Hong KongAKESF.USA4RY.Germany IPO Date
2020-04-27Description
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.5 | |||||
Debt-to-EBITDA | -6.13 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 6.6 | |||||
Beneish M-Score | -1.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 48.9 | |||||
3-Year EBITDA Growth Rate | 19 | |||||
3-Year EPS without NRI Growth Rate | 5.6 | |||||
3-Year FCF Growth Rate | 8.4 | |||||
3-Year Book Growth Rate | 45.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 51.38 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.4 | |||||
9-Day RSI | 56.77 | |||||
14-Day RSI | 48.95 | |||||
3-1 Month Momentum % | -7.34 | |||||
6-1 Month Momentum % | 8.24 | |||||
12-1 Month Momentum % | 30.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.14 | |||||
Quick Ratio | 4.71 | |||||
Cash Ratio | 4.16 | |||||
Days Inventory | 459.69 | |||||
Days Sales Outstanding | 93.19 | |||||
Days Payable | 248.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.1 | |||||
Shareholder Yield % | -5.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.65 | |||||
Operating Margin % | -27.73 | |||||
Net Margin % | -36.4 | |||||
EBITDA Margin % | -24.45 | |||||
FCF Margin % | -56.78 | |||||
OCF Margin % | -31.03 | |||||
ROE % | -15.1 | |||||
ROA % | -8.01 | |||||
ROIC % | -17.09 | |||||
3-Year ROIIC % | 15.66 | |||||
ROC (Joel Greenblatt) % | -25.8 | |||||
ROCE % | -8.45 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 952.27 | |||||
PS Ratio | 23.68 | |||||
PB Ratio | 8.11 | |||||
Price-to-Tangible-Book | 8.38 | |||||
EV-to-EBIT | -71.24 | |||||
EV-to-Forward-EBIT | -133.6 | |||||
EV-to-EBITDA | -96.2 | |||||
EV-to-Forward-EBITDA | 164.32 | |||||
EV-to-Revenue | 23.52 | |||||
EV-to-Forward-Revenue | 14.05 | |||||
EV-to-FCF | -41.41 | |||||
Price-to-GF-Value | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 16.9 | |||||
| Price-to-Net-Cash | 33.79 | |||||
Earnings Yield (Greenblatt) % | -1.4 | |||||
FCF Yield % | -2.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akeso Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 369.864 | ||
| EPS (TTM) (€) | -0.149 | ||
| Beta | 0.1802 | ||
| 3-Year Sharpe Ratio | 0.84 | ||
| 3-Year Sortino Ratio | 1.76 | ||
| Volatility % | 84.25 | ||
| 14-Day RSI | 48.95 | ||
| 14-Day ATR (€) | 0.424863 | ||
| 20-Day SMA (€) | 9.92475 | ||
| 12-1 Month Momentum % | 30.76 | ||
| 52-Week Range (€) | 9.164 - 19.3 | ||
| Shares Outstanding (Mil) | 921.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akeso Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akeso Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-27 20:00 | In 59 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 56 days | ||
| General meeting for 2025 | 2026-06-30 14:00 | 9.19 (-1.10%) | ||
| Annual report for 2025 | 2026-04-29 | 14.73 (+0.20%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-27 20:00 | 18.30 (-1.08%) | ||
| Second quarter earnings results for 2025 | 2025-08-26 | 18.90 (+3.85%) | ||
| General meeting for 2024 | 2025-06-30 14:00 | 9.85 (+0.00%) | ||
| Annual report for 2024 | 2025-04-29 | 9.75 (-3.47%) | ||
| Second quarter earnings conference call for 2024 | 2024-08-29 | 5.10 (-0.97%) | ||
| Second quarter earnings results for 2024 | 2024-08-28 | 5.30 (+0.00%) |
Show
Entries
Akeso Inc Frequently Asked Questions
What is Akeso Inc(FRA:4RY)'s stock price today?
The current price of FRA:4RY is €10.48. The 52 week high of FRA:4RY is €19.30 and 52 week low is €9.16.
When is next earnings date of Akeso Inc(FRA:4RY)?
The next earnings date of Akeso Inc(FRA:4RY) is 2026-08-26 Est..
Does Akeso Inc(FRA:4RY) pay dividends? If so, how much?
Akeso Inc(FRA:4RY) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023 | 2023-12-05 |
Articles on Akeso Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers